Gastro Rest Capsule SR is a pharmaceutical formulation combining Levosulpiride 75 mg and Rabeprazole 20 mg, designed for the effective management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, facilitates prokinetic activity by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms of dyspepsia, gastroparesis, and functional dyspepsia. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, providing symptomatic relief from acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, optimizing efficacy and improving patient compliance by reducing dosing frequency. Gastro Rest Capsule SR is indicated for patients presenting with upper gastrointestinal symptoms including heartburn, epigastric pain, bloating, nausea, and vomiting associated with acid peptic disorders and motility disturbances. It should be used under medical supervision, with caution in patients with a history of hypersensitivity to either component, and is contraindicated in those with gastrointestinal obstruction or prolactin-dependent tumors. Adverse effects may include mild gastrointestinal disturbances, headache, or dizziness. Overall, Gastro Rest Capsule SR offers a synergistic approach by combining acid suppression and prokinetic action, enhancing symptomatic relief and improving quality of life in affected individuals.